Profit before tax (PBT) was at Rs 27.39 crore in Q3 FY25, up 151.75% as against Rs 10.88 crore reported in the same period a year ago.
Total expense jumped 13.79% year on year to Rs 34.90 crore during the quarter. Employee benefit expense stood at Rs 6.56 crore (up 17.56% YoY), while cost of materials consumed was at Rs 1.81 crore (up 14.56% YoY) during the period under review.
The company’s revenue from the active pharmaceutical ingredients business was at Rs 6.25 crore (down 3.55% YoY), while the real estate business came in at Rs 51.67 crore (up 57.29% YoY) during the period under review.
On a 9-month basis, the net profit surged 68.8% to Rs 120.83 crore on a 49.04% rise in revenue from operations to Rs 161.62 crore in 9M FY25 over 9M FY24.
Alembic is dealing in the Active Pharmaceutical Ingredient (API) Business and Real Estate Business.
Shares of Alembic fell 1.69% to Rs 110.85 on the BSE.
Alembic consolidated net profit rises 6.50% in the December 2024 quarter
08 - Feb - 2025 12:00 | 81 days ago
Net profit of Alembic rose 6.50% to Rs 65.39 crore in the quarter ended December 2024 as against Rs 61.40 crore during the previous quarter ended December 2023. Sales rose 47.30% to Rs 57.92 crore in the quarter ended December 2024 as against Rs 39.32 crore during the previous quarter ended December 2023.
Alembic consolidated net profit rises 6.50% in the December 2024 quarter
08 - Feb - 2025 12:00 | 81 days ago
Net profit of Alembic rose 6.50% to Rs 65.39 crore in the quarter ended December 2024 as against Rs 61.40 crore during the previous quarter ended December 2023. Sales rose 47.30% to Rs 57.92 crore in the quarter ended December 2024 as against Rs 39.32 crore during the previous quarter ended December 2023.
Alembic consolidated net profit rises 33.46% in the September 2024 quarter
08 - Nov - 2024 12:00 | 173 days ago
Net profit of Alembic rose 33.46% to Rs 121.02 crore in the quarter ended September 2024 as against Rs 90.68 crore during the previous quarter ended September 2023. Sales rose 63.91% to Rs 52.91 crore in the quarter ended September 2024 as against Rs 32.28 crore during the previous quarter ended September 2023.
Profit before tax (PBT) was at Rs 27.39 crore in Q3 FY25, up 151.75% as against Rs 10.88 crore reported in the same period a year ago.
Total expense jumped 13.79% year on year to Rs 34.90 crore during the quarter. Employee benefit expense stood at Rs 6.56 crore (up 17.56% YoY), while cost of materials consumed was at Rs 1.81 crore (up 14.56% YoY) during the period under review.
The company’s revenue from the active pharmaceutical ingredients business was at Rs 6.25 crore (down 3.55% YoY), while the real estate business came in at Rs 51.67 crore (up 57.29% YoY) during the period under review.
On a 9-month basis, the net profit surged 68.8% to Rs 120.83 crore on a 49.04% rise in revenue from operations to Rs 161.62 crore in 9M FY25 over 9M FY24.
Alembic is dealing in the Active Pharmaceutical Ingredient (API) Business and Real Estate Business.
Shares of Alembic fell 1.69% to Rs 110.85 on the BSE.
Alembic consolidated net profit rises 6.50% in the December 2024 quarter
08 - Feb - 2025 12:00 | 81 days ago
Net profit of Alembic rose 6.50% to Rs 65.39 crore in the quarter ended December 2024 as against Rs 61.40 crore during the previous quarter ended December 2023. Sales rose 47.30% to Rs 57.92 crore in the quarter ended December 2024 as against Rs 39.32 crore during the previous quarter ended December 2023.
Alembic consolidated net profit rises 33.46% in the September 2024 quarter
08 - Nov - 2024 12:00 | 173 days ago
Net profit of Alembic rose 33.46% to Rs 121.02 crore in the quarter ended September 2024 as against Rs 90.68 crore during the previous quarter ended September 2023. Sales rose 63.91% to Rs 52.91 crore in the quarter ended September 2024 as against Rs 32.28 crore during the previous quarter ended September 2023.
Profit before tax (PBT) was at Rs 27.39 crore in Q3 FY25, up 151.75% as against Rs 10.88 crore reported in the same period a year ago.
Total expense jumped 13.79% year on year to Rs 34.90 crore during the quarter. Employee benefit expense stood at Rs 6.56 crore (up 17.56% YoY), while cost of materials consumed was at Rs 1.81 crore (up 14.56% YoY) during the period under review.
The company’s revenue from the active pharmaceutical ingredients business was at Rs 6.25 crore (down 3.55% YoY), while the real estate business came in at Rs 51.67 crore (up 57.29% YoY) during the period under review.
On a 9-month basis, the net profit surged 68.8% to Rs 120.83 crore on a 49.04% rise in revenue from operations to Rs 161.62 crore in 9M FY25 over 9M FY24.
Alembic is dealing in the Active Pharmaceutical Ingredient (API) Business and Real Estate Business.
Shares of Alembic fell 1.69% to Rs 110.85 on the BSE.
Alembic consolidated net profit rises 6.50% in the December 2024 quarter
08 - Feb - 2025 12:00 | 81 days ago
Net profit of Alembic rose 6.50% to Rs 65.39 crore in the quarter ended December 2024 as against Rs 61.40 crore during the previous quarter ended December 2023. Sales rose 47.30% to Rs 57.92 crore in the quarter ended December 2024 as against Rs 39.32 crore during the previous quarter ended December 2023.
Alembic consolidated net profit rises 6.50% in the December 2024 quarter
08 - Feb - 2025 12:00 | 81 days ago
Net profit of Alembic rose 6.50% to Rs 65.39 crore in the quarter ended December 2024 as against Rs 61.40 crore during the previous quarter ended December 2023. Sales rose 47.30% to Rs 57.92 crore in the quarter ended December 2024 as against Rs 39.32 crore during the previous quarter ended December 2023.
Alembic consolidated net profit rises 33.46% in the September 2024 quarter
08 - Nov - 2024 12:00 | 173 days ago
Net profit of Alembic rose 33.46% to Rs 121.02 crore in the quarter ended September 2024 as against Rs 90.68 crore during the previous quarter ended September 2023. Sales rose 63.91% to Rs 52.91 crore in the quarter ended September 2024 as against Rs 32.28 crore during the previous quarter ended September 2023.
